Background: A role for inflammation, and consequently of non-steroideal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty.
Introduction
The use of aspirin and other non-steroid anti-inflammatory drugs (NSAID) has been associated with a lower risk of colorectal and possibly breast cancer [1] . The proposed mechanisms of their chemopreventive action involves blocking cyclo-oxygenase activity, with subsequent inhibition of the synthesis of prostaglandins, prostacyclins and thromboxane, which, in turn, regulate inflammation and several mechanisms of cellular proliferation. As these mechanisms are not tissue-specific, they might also be relevant for cancer at other sites. A role for inflammation in ovarian carcinogenesis has been proposed [2] , possibly in relation to ovulation, which, in turn, has been related to ovarian carcinogenesis [3, 4] .
Epidemiological evidence on the relation between use of NSAID and the risk of ovarian cancer is scanty. A hospital-based case-control study [5] conducted in Athens on 189 cases of ovarian cancer found an odds ratio (OR) of 0.51 (95% confidence intervals (95% CI): 0.26-1.02) for women using analgesics (mostly salicylates) twice per week or more. A population-based case-control study [6] , conducted in the USA on 563 cases, found an OR of 0.75 (95% CI: 0.52-1.10) for continuous use of aspirin at least once a week for at least six months.
We investigated the association between regular use of aspirin and risk of ovarian cancer in Italy.
Patients and methods
The data were derived from a case-control study conducted between January 1992 and September 1999 in four Italian areas: Greater Milan, the provinces of Pordenone and Gorizia (northern Italy), the province of Latina (central Italy), and the urban area of Naples (southern Italy). Less than 4% of cases and controls approached for interview refused to participate. Information on aspirin use was included in December 1993.
Cases were 749 women, aged 18-80 years (median age 56), with incident, histologically confirmed ovarian cancer, admitted to the major teaching and general hospitals in the areas under surveillance. Controls were 898 women, aged 17-80 years (median age 58), residing in the same areas and admitted for acute conditions, unrelated to known or likely risk factors for ovarian cancer, to the same network of hospitals where cases had been identified (29% traumatic conditions, 28% acute non-traumatic orthopedic disorders, 11% acute surgical conditions and 32% miscellaneous other illnesses, such as eye, ear, nose, throat and dental disorders). Cases and controls were not singularly matched: their distribution by age, education and parity is reported in Table 1 .
The structured questionnaire included information on personal characteristics and habits, education and other socio-economic factors, anthropometric measures, physical activity, smoking, alcohol and coffee consumption, a validated food frequency section, gynecological and obstetric data, selected medical history, and history of lifetime use of oral contraceptives, hormone replacement therapy and aspirin. The information on aspirin intake included indication, age at starting use. frequency and duration of use; regular intake was defined as use at least once a week for more than six consecutive months. A comprehensive list of the main salicylate-containing preparations in Italy was supplied to facilitate recall.
OR of ovarian cancer and the corresponding 95% CI according to various measures of aspirin use were derived using unconditional multiple logistic regression [7] , including terms for study center, age (11 levels plus a continuous term), year of interview, education (3 levels), parity (5 levels), age at menopause (3 levels), body mass index (2 levels) and oral contraceptive use (never/ever).
Results
The distribution of cases and controls by age, education and parity is shown in Table 1 , together with the corresponding OR and 95% CI. Ovarian cancer risk increased with years of education (OR 2.07 for Js 12 years of education) and decreased with number of children (OR 0.59 for ^ 3 children). Table 2 gives the distribution of ovarian cancer cases and the comparison group according to various measures of aspirin use. A total of 33 (4.4%) cases and 50 (5.6%) controls reported regular use of aspirin. The corresponding multivariate OR was 0.93 for continued regular use, 1.38 for current regular use and 0.72 for former regular use. The OR was not significantly different from unity in women regularly using aspirin either for < 5 years (OR 0.77) or for ~^ 5 years (OR 1.24), in women starting regular use < 10 years before (OR 0.82) or Js 10 years before (OR 1.03), in women starting regular use when younger than 40 years (OR 1.49) and when aged ^40 years (OR 0.69), and in women taking aspirin for analgesia (OR 1.06) or for cardiovascular prevention (OR 0.79) regularly. The OR for continued regular aspirin use were not heterogeneous in women with a diagnosis of ovarian cancer when aged < 60 (OR 1.31, 95% CI: 0.60-2.85) and ^ 60 years (OR 0.64, 95% CI: 0.27-1.55).
Discussion
The present study provides no support for the hypothesis that regular use of aspirin may reduce the risk of ovarian cancer. Our results are in agreement with cohort studies of women with rheumatoid arthritis, who chronically use NSAID [8] [9] [10] [11] . In the Rochester rheumatoid arthritis cohort [8] there was one case of ovarian cancer on 2.1 expected, and in a cohort of nearly 8000 Swedish women [9] there were 30 cases of ovarian cancer, corresponding to a standardized incidence ratio of 0.96. In a Danish cohort [10] of more than 14,000 women with rheumatoid arthritis the relative risk for ovarian cancer was 1.0, based on 50 incident cases. In a Canadian cohort [11] of 862 patients with rheumatoid arthritis, 95% of whom took aspirin regularly, the standardized incidence ratio was 0.89 based on 5 cases.
Our study, although large, includes only a limited population of regular aspirin users, reflecting the pattern of the drug use in Italy [12] , characterized by a relatively infrequent use for antithrombosis, particularly among women during ovulatory years. Another limitation of the study is that some of the diagnostic categories of the controls may be associated with increased aspirin use. However, separate comparison of cases with each of the major diagnostic categories of controls yielded similar results, providing reassurance against potential selection bias. The frequency of regular aspirin users was 4.0% among subjects with traumatic conditions, 5.1% among those with nontraumatic orthopedic diseases, 5.7% among those with surgical conditions and 6.3% among patients with other miscellaneous illnesses. Moreover, an increased use of aspirin by hospital controls compared with the general population would lead to a reduced estimation of risk.
Strengths of the study are the similar catchment areas for cases and controls, the high participation rate, and the choice of hospital controls, which are preferable with reference to reliability and validity of information on drug use, since cases and controls are similarly sensitized towards various aspects of their medical history [13] . Allowance for a large number of potential confounding factors, including body mass index, parity and oral contraceptive use, did not materially modify any of the risk estimates.
